Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "Quinapril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor." assertion.
- association label ""Oxybutynin chloride is contraindicated in patients with untreated angle closure glaucoma and in patients with untreated narrow anterior chamber angles since anticholinergic drugs may aggravate these conditions. It is also contraindicated in partial or complete obstruction of the gastrointestinal tract, paralytic ileus, intestinal atony of the elderly or debilitated patient, megacolon, toxic megacolon complicating ulcerative colitis, severe colitis, and myasthenia gravis. It is contraindicated in patients with obstructive uropathy and in patients with unstable cardiovascular status in acute hemorrhage. Oxybutynin chloride is contraindicated in patients who have demonstrated hypersensitivity to the product."" assertion.
- association label ""Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. It is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. Long-term administration of acetazolamide is contraindicated in patients with chronic non- congestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure."" assertion.
- association label ""KETEK is contraindicated in patients with myasthenia gravis. KETEK is contraindicated in patients with previous history of hepatitis and/or jaundice associated with the use of KETEK tablets, or any macrolide antibiotic. KETEK is contraindicated in patients with a history of hypersensitivity to telithromycin and/or any components of KETEK tablets, or any macrolide antibiotic. Concomitant administration of KETEK with cisapride or pimozide is contraindicated. (See CLINICAL PHARMACOLOGY, Drug-drug Interactions PRECAUTIONS Concomitant administration of KETEK and colchicine is contraindicated in patients with renal or hepatic impairment. (See WARNINGS, Drug Interactions PRECAUTIONS, Drug interactions"" assertion.
- association label ""ELLENCE is contraindicated in patients with: Severe myocardial insufficiency [see Warnings and Precautions (5.1) Recent myocardial infarction or severe arrhythmias, or previous treatment with maximum cumulative dose of anthracyclines [see Warnings and Precautions (5.1) Severe persistent drug-induced myelosuppression [see Warnings and Precautions (5.4) Severe hepatic impairment (defined as Child-Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Warnings and Precautions (5.5) Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones [see Adverse Reactions (6.1) Severe myocardial insufficiency ( 4 Recent myocardial infarction ( 4 Severe persistent drug-induced myelosuppression ( 4 Severe hepatic impairment ( 4 Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones ( 4"" assertion.
- association label ""Trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Do not co-administer aliskiren with trandolapril in patients with diabetes (see PRECAUTIONS, Drug Interactions Trandolapril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer trandolapril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS"" assertion.
- association label ""All diuretics, including ethacrynic acid, are contraindicated in anuria. If increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. In a few patients this diuretic has produced severe, watery diarrhea. If this occurs, it should be discontinued and not used again. Until further experience in infants is accumulated, therapy with oral and parenteral ethacrynic acid is contraindicated. Hypersensitivity to any component of this product."" assertion.
- association label ""The use of Zileuton Extended-Release Tablets is contraindicated in patients with: Active liver disease or persistent hepatic function enzyme elevations greater than or equal to 3 times the upper limit of normal (>=3xULN) [see Warnings and Precautions (5) Use in Specific Populations (8.7) A history of allergic reaction to zileuton or any of the ingredients of Zileuton Extended Release Tablets (e.g., rash, eosinophilia, etc.). Active liver disease or persistent hepatic function enzyme elevations >=3 times the upper limit of normal. ( 4 5.1 History of allergic reaction to Zileuton or any of the ingredients of Zileuton Extended-Release Tablets. ( 4"" assertion.
- association label ""Coadministration with stavudine allopurinol or ribavirin is contraindicated. ( 4 VIDEX EC is contraindicated when coadministered with the following medications: Stavudine- potential for serious and/or life-threatening events, notably pancreatitis, lactic acidosis, hepatotoxicity, and peripheral neuropathy [ see Warnings and Precautions 5.1 5.2 5.3 5.5 Allopurinol- systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [ see Clinical Pharmacology (12.3) Ribavirin- exposures of the active metabolite of didanosine (dideoxyadenosine 5'-triphosphate) are increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin."" assertion.
- association label ""The intravenous administration. Hypervitaminosis A. Sensitivity to any of the ingredients in this preparation. Use in Pregnancy:"" assertion.
- association label ""ORILISSA is contraindicated in women: Who are pregnant [see Use in Specific Populations ( 8.1 With known osteoporosis because of the risk of further bone loss [see Warnings and Precautions ( 5.1 With severe hepatic impairment [see Use in Specific Populations ( 8.7 12.3 With concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil) [see Drug Interactions ( 7.2 Pregnancy ( 4 Known osteoporosis ( 4 Severe hepatic impairment ( 4 Strong organic anion transporting polypeptide (OATP) 1B1 inhibitors ( 4"" assertion.
- association label ""Terbinafine tablets are contraindicated in patients with: Terbinafine tablets are contraindicated in patients with: * History of allergic reaction to oral terbinafine because of the risk of anaphylaxis * History of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see Adverse Reactions (6.2) * Chronic or active liver disease [see Warnings and Precautions (5.1) History of allergic reaction to oral terbinafine because of the risk of anaphylaxis. ( 4 Chronic or active liver disease. ( 4"" assertion.
- association label ""TEGSEDI is contraindicated in patients with: Platelet count below 100 x 10 9 [see Warnings and Precautions ( 5.1 History of acute glomerulonephritis caused by TEGSEDI [see Warnings and Precautions ( 5.2 History of a hypersensitivity reaction to TEGSEDI [see Warnings and Precautions ( 5.7 Platelet count less than 100 x 10 9 4 5.1 History of acute glomerulonephritis caused by TEGSEDI ( 4 5.2 Patients with a history of a hypersensitivity reaction to TEGSEDI ( 4 5.7"" assertion.
- association label ""VISUDYNE is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation [ see Adverse Reactions (6) VISUDYNE is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation. ( 4"" assertion.
- association label "Acute intermittent porphyria as well as allergic or idiosyncratic reactions to meprobamate or related compounds such as carisoprodol, mebutamate, tybamate, or carbromal." assertion.
- association label ""Transderm Scop is contraindicated in the following populations: Patients with angle closure glaucoma. [ see Adverse Reactions (6)] Persons who are hypersensitive to the drug scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. [see Drug Interactions (7) Description (11) Patients with angle closure glaucoma ( 4 6.2 Persons who are hypersensitive to scopolamine or to other belladonna alkaloids ( 4 7"" assertion.
- association label ""Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug. It is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest (see WARNINGS"" assertion.
- association label ""Ranolazine extended-release tablets are contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions ( 7.1 Taking inducers of CYP3A [see Drug Interactions ( 7.1 With liver cirrhosis [see Use in Specific Populations (8.6 Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) ( 4 7.1 CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) ( 4 7.1 Liver cirrhosis ( 4 8.6"" assertion.
- association label ""Physostigmine Salicylate Injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). For post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine."" assertion.
- association label ""Mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. Mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes."" assertion.
- association label "Edetate calcium disodium should not be given during periods of anuria, nor to patients with active renal disease or hepatitis." assertion.
- association label "Miotics are contraindicated where constriction is undesirable; such as acute iritis, and in those subjects showing hypersensitivity to any component of this preparation." assertion.
- association label "Amobarbital sodium is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident." assertion.
- association label "Hypertension; toxemia; pregnancy; and hypersensitivity." assertion.
- association label ""Zafirlukast tablets are contraindicated in patients who are hypersensitive to zafirlukast or any of its inactive ingredients. Zafirlukast tablets are contraindicated in patients with hepatic impairment including hepatic cirrhosis."" assertion.
- association label "Cevimeline hydrochloride is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma." assertion.
- association label ""Active uveal inflammation. Most cases of angle-closure glaucoma without iridectomy, due to the possibility of increasing angle block. Hypersensitivity to the active or inactive ingredients."" assertion.
- association label "Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D." assertion.
- context label "adults" assertion.
- association label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]." assertion.
- association label "In some cases, this may be justifiable–for example, escitalopram is approved for treatment of generalized anxiety disorder, but its enantiomer, citalopram, is not [15]." assertion.
- context label "adults" assertion.
- MONDO_0001942 label "generalized anxiety disorder" assertion.
- MONDO_0001942 label "generalized anxiety disorder" assertion.
- MONDO_0001942 label "generalized anxiety disorder" assertion.
- MONDO_0001942 label "generalized anxiety disorder" assertion.
- association label "Furthermore, the efficacy of trazodone in the treatment of primary insomnia or generalized anxiety disorders alone is weak, and the use of certain anti-depressants over FDA-approved benzodiazepines in anxiety disorders has been shown to be associated with a higher risk of adverse drug events [18, 32]." assertion.
- context label "adults" assertion.
- association label "Information only available from Table 3" assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "Anti-psychotics had the second highest rate of off-label prescription (28.6%)–the most common off-label use was for major depressive disorder." assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- MONDO_0024614 label "neurotic depression" assertion.
- MONDO_0024614 label "neurotic depression" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- association label "In a study published by Wilcox et al. [19], the alpha- 1 adrenergic receptor antagonist prazosin did not differ from placebo in reducing alcohol consump- tion in 36 participants." assertion.
- cohort label "Adults" assertion.
- association label "Only a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- context label "adults" assertion.
- association label "It has been tested in multiple clinical trials since it could be promising in AUD treatment. Topiramate decreases reinforcing effects of alcohol and craving. A meta-analysis, based on data from seven random studies (2003-2014), suggested that topiramate might have beneficial effects in AUD treatment but because of its many side effects, the use is limited. The most common side effects are cognitive dysfunction, paresthesia, and taste abnormalities. " assertion.
- DOID_1574 label "alcohol use disorder" assertion.
- DOID_1574 label "alcohol use disorder" assertion.
- DOID_1574 label "alcohol use disorder" assertion.
- DOID_1574 label "alcohol use disorder" assertion.
- association label "Studies have been conducted on both the main drugs used in alcohol dependence (NTX and ACA) and on the off-label drugs (topiramate, ondansetron, sertraline and olanzapine)." assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia. " assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia. " assertion.
- association label "Long-term prophylactic treatment relies on lithium, off-label use of valproate, and growing use of modern antipsychotics." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "While trazodone is approved for the treatment of depression, the off-label use of this medication for insomnia has surpassed its usage as an antidepressant." assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. Table 1" assertion.
- context label "children and adolescents" assertion.
- MONDO_0005379 label "Neurotic disorder" assertion.
- MONDO_0005379 label "Neurotic disorder" assertion.
- MONDO_0005379 label "Neurotic disorder" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- MONDO_0005352 label "Conduct disorder" assertion.
- MONDO_0005352 label "Conduct disorder" assertion.
- MONDO_0005352 label "Conduct disorder" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. Quetiapine was mainly prescribed for neurotic disorder or depression, while aripiprazole was prescribed most frequently for conduct disorder or neurotic disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- MONDO_0005303 label "Drug dependence" assertion.
- MONDO_0005303 label "Drug dependence" assertion.
- MONDO_0005303 label "Drug dependence" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- context label "Children" assertion.